Table 1 Clinical characteristics of 388 patients with NSCLC
From: Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
EGFR-TKIs n (%) | |||||
|---|---|---|---|---|---|
Characteristic | Total | Gefitinib/ Erlotinib | Afatinib | Osimertinib | P‡ |
388 | 183 | 55 | 150 | ||
Median Age (Range) | 73 (26–87) | 65 (32–79) | 72 (44–92) |  < 0.0001 | |
Gender | |||||
 Male | 149 | 64 (35.0) | 29 (52.7) | 56 (37.3) | 0.0563 |
 Female | 239 | 119 (65.0) | 26 (47.3) | 94 (62.7) | |
Smoking statusa | |||||
 Never | 236 | 117 (64.6) | 26 (49.0) | 93 (63.7) | 0.0868 |
 Former | 104 | 49 (27.1) | 16 (30.2) | 39 (26.7) | |
 Current | 40 | 15 (8.3) | 11 (20.8) | 14 (9.6) | |
PS | |||||
 0 | 230 | 110 (60.1) | 33 (60.0) | 87 (58.0) | 0.7914 |
 1 | 99 | 42 (23.0) | 15 (27.3) | 42 (28.0) | |
 ≧2 | 59 | 31 (16.9) | 7 (12.7) | 21 (14.0) | |
Stage | |||||
 III | 15 | 9 (4.9) | 0 (0.0) | 6 (4.0) | 0.8257 |
 IV | 270 | 125 (68.3) | 40 (72.7) | 105 (70.0) | |
 Recurrence | 103 | 49 (26.8) | 15 (27.3) | 39 (26.0) | |
Mutation statusb | |||||
 Exon 19 deletion | 188 | 76 (41.8) | 44 (80.0) | 68 (45.3) |  < 0.0001 |
 L858R | 199 | 106 (58.2) | 11 (20.0) | 82 (54.7) | |
Metastasis | |||||
 Pleura | 144 | 72 (39.3) | 16 (29.1) | 56 (37.3) | 0.3848 |
 Contralateral lung | 92 | 40 (21.9) | 12 (21.8) | 40 (26.7) | 0.5541 |
 Bone | 160 | 68 (37.2) | 29 (52.7) | 63 (42.0) | 0.1171 |
 Brain | 118 | 50 (27.3) | 20 (36.4) | 48 (32.0) | 0.3820 |
 Liver | 34 | 14 (7.7) | 3 (5.5) | 17 (11.3) | 0.3205 |
 Adrenal | 26 | 13 (7.1) | 6 (10.9) | 7 (4.7) | 0.2728 |